Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Myelofibrosis
NCT01392443Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in myelofibrosis (MF), sponsored by Novartis. Primary endpoint: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at 24 weeks. Started Oct 2010; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01392443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392443.